source
- AstraZeneca shares tumble after heart drug trial failsAstraZeneca's stock fell in early trading on Thursday after the company disclosed that its experimental heart disease therapy, developed with Ionis Pharmaceuticals, did not meet primary endpoints i…
- Eli Lilly leads biotech M&A in H1, leveraging obesity drug success and trillion-dollar scaleEli Lilly, already the largest pharmaceutical company, has emerged as a leading buyer of biotech assets in the first half of 2026. Its trillion-dollar market size and recent successes in obesity t…